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INTRODUCTION 
Hypokalemia is a common clinical problem. It is defined as serum potassium less than 
3.5meq per litre. The route through which potassium enters the body is oral and 
intravenous after which it gets stored mainly in the cells.  It is the most abundant 
cation present in the human body. The total potassium content in the body is about 
4,000 meq (1). 98% of this is in the intracellular fluid compartment (2). The 
extracellular fluid contains only about 60 meq(3). The maximum storage of potassium 
is in the skeletal muscles (2600 meq)(1).The ratio of the concentration of potassium 
within the cells to extracellular fluid potassium concentration reflects the resting 
membrane potential (RMP)(2) which remains constant .The normal level of potassium 
between cells and body fluids is maintained by the Na-K-ATPase pump located on the 
cell membrane. Through this pump 3 sodium ions move out of the cells in exchange 
for 2 potassium ions into the cell. Most of this potassium that enters the cells exits by 
a potassium channel. Every potassium ion that comes out of this channel carries one 
positive charge. This maintains most of the RMP. There are two hormones which 
cause a shift of potassium into the cells. These are insulin and catecholamines. They 
also bring about the movement of sodium out of the cells; but, by different 
mechanisms. The action of insulin is through the Na-H-exchanger(4)  whereas 
catecholamines act through the Na-K-ATPase(5). Potassium is excreted from the body 
through the kidneys. Here, tubular reabsorption occurs in the proximal convulated 
tubule as well as the loop of henle whereas active secretion occurs in the principal 
cells of the connecting tubule and cortical collecting tubule. In these areas, sodium is 
reabsorbed in exchange for potassium. This actively secreted potassium is the one 
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which gets excreted from the body. The hormone which plays a major role in this 
process is aldosterone(6,7).  
During times of increase is the body’s potassium, aldosterone is released. It acts on the 
principal cells which in turn increases the active secretion of potassium in exchange 
for sodium leading to normalization of body’s potassium level. 
There are three ways in which the kidney responds to hypokalemia:  
a)  Hypokalemia causes a block to the secretion of aldosterone which leads to 
decreased sodium reabsorption in the distal convulated tubule and hence 
decreased active secretion of potassium leading to conservation of body’s 
potassium (8,9).  
b) Hypokalemia causes stimulation of the release of rennin and angiotensin II. 
These hormones cause a down regulation of the potassium secreting channels 
in the distal convulated tubules which in turn leads to decrease in the excretion 
of potassium(10).  
c) Hypokalemia causes activation of H-K-ATPase pump present in the apical 
membrane of type A intercalated cells, which are located adjacent to the 
principal cells in the cortical collecting tubules(11). The function of this pump 
is to take in potassium and secrete hydrogen. 
Therefore, the mechanisms by which hypokalemia occur are: 
i) Decreased intake 
ii) Increased translocation into the cells 
iii) Increased excretion (renal, gastrointestinal tract, sweat) 
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OBJECTIVES 
The following are the objectives of this study: 
1. To find the proportion of patients with hypokalemia and 
its causes in adult medical wards 
2. The dose and duration of potassium( intravenous or oral or  
both) required for correction 
3. Correlation of hypokalemia with mortality 
4. Association of hypokalemia with other comorbidities  
5. Association of ECG changes with severity of hypokalemia 
LITERATURE REVIEW 
DEFINITION 
Potassium is an inorganic metal with an atomic weight of 39. It is the most abundant 
cation in the body.  Normal serum potassium is 3.5 to 5.5 meq per litre(2),but the 
plasma potassium is 0.5 meq per litre lower(12). It is important to note that the total 
body potassium is lower in females and in older patients, but the serum potassium is 
not related to gender and age(12).This clinical range of normal serum potassium is 
narrow and very minimal deviation of serum potassium from this range ( as small as 
less than 1.0 meq per litre) can lead to significant defects in the body which can even 
result in the death of the patient(13,14). Although this much deviation (of only 1.0 
meq per litre) in concentration of serum potassium is small in absolute terms, the 
change in the intracellular to extracellular potassium ratio is by 25%(12). This is the 
reason why rapid evaluation of any deviation from the normal range of serum 
11 
 
potassium (hypokalemia or hyperkalemia) is needed and, whenever it is indicated, to 
treat the same is of critical importance. 
GLOBAL EPIDEMIOLOGY 
Hypokalemia is a common electrolyte abnormality encountered in hospitalized 
patients. Record linkage analysis of hypokalemia in patients who were hospitalized, 
done in Glasgow Royal Infirmary for a period of 3 years, showed the following 
results(15) : 
a) At admission the number of patients having hypokalemia with a serum 
potassium of less than 3.5 meq per litre was 21% 
b) Amongst these, patients who had clinically significant hypokalemia was 5.2 % 
with the value of serum potassium being less than 3.0 meq per litre. 
c) There was significant association of hypokalemia with an increase in hospital 
mortality. Patients who died mostly had a serum potassium < 2 meq per litre 
(mortality 34%) and 2.0 to 2.4 meq per litre (mortality 26%) 
d) A statistically significant gender difference was found with the female gender 
being more predisposed to the development of the same (a similar association 
had been reported previously from a study done in Denmark by Krakauer and 
Lauritzen in 1978). The reason as to why this kind of difference exists is not 
clear. 
e) A strong and consistent relationship between hypokalemia and cancer as the 
main diagnosis at discharge was observed. Hematological malignancies were 
the most important cause for severe hypokalemia. On the other hand, tumors of 
the gastrointestinal tract seemed to cause hypokalemia of lesser degree of 
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severity. Relationship with other types of tumors was not statistically 
significant. 
f) Most likely underlying cause (overall) was drugs (in about 38% of cases). 
Amongst the drugs, the most common one responsible for hypokalemia was 
found to be diuretics(62%) followed by steroids(9%) and then insulin(7%) and 
hydroxycobalamine(7%). Amongst patients on diuretics, the patients mostly 
had mild to moderate (2.5 to 3.4 meq per litre)  hypokalemia both with 
thiazides and loop diuretics. The other mentioned drugs did not seem to 
correlate with the degree of hypokalemia. Intravenous fluid administration with 
insufficient potassium supplementation was also found to be responsible for 
hypokalemia. 
Another study done in Jakarta, Indonesia in 2006 amongst patients with infectious 
diseases reported the following findings(16): 
a) The age range was 14 to 70 years 
b) Prevalence of hypokalemia among the hospitalised patients was 23% at 
admission and 37% during hospital stay. 5 % had serum potassium level less 
than 3 meq per litre. 
c) Factors which seemed to be responsible for the development of hypokalemia 
were decreased intake of potassium in the diet and shift of potassium into the 
cells. 
d) Most common associated infectious condition was found to be dengue. 
e) The mean level of hypokalemia at admission was found to be 3.11 + SD 0.37 
meq per litre and during hospitalisation was 3.13 + SD 0.25 meq per litre. 
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f) The  ratio of hypokalemia in terms of severity , mild: moderate: severe , at 
admission  was found to be 22:2:1 and that at discharge , moderate: severe, was 
19:1 
In a recent cohort study done in 2014 among patients who were admitted with 
hypokalemia in acute critical care setting in a University hospital located in 
Denmark(17) , 
a) Hypokalemia was found to occur in 16.8% amongst patients who were getting 
admitted for the first time, with plasma potassium level of <2.9 mmol/L 
occurring in 3.3% of patients. The former was notably lower than that which 
has been reported in previous studies- 24.9% and 20.4%. 
b) The in-hospital mortality rate among patients with hypokalemia ( serum 
potassium<3.0 mmol/L) was 7.9%( 0-7 day mortality)  and  9.4%( 8-30 day 
mortality) 
c) The prognostic factors for both the groups were found to be an increase in the 
age and Charlson co-morbidity index. There was no significant prognostic 
association found between prognosis and the continuing usage of diuretics or 
beta adrenergic agents. 
Usually hypokalemia does not produce any symptoms and identified only on routine 
screening, but, severe hypokalemia can lead to serious problems like cardiac 
arrhythmias, paralysis, rhabdomyolysis, and diaphragmatic paresis. Many studies have 
looked into the causes and the symptoms of hypokalemia. However, the risk factors 
and prognosis of hypokalemia have mostly been studied in patients with 
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cardiovascular or chronic kidney disease(18–22). It was seen in these studies that even 
mild to moderate hypokalemia was associated with increase in morbidity and 
mortality upto 50%. It is not clear as to whether such an association exists in patients 
with other comorbidities. 
Several electrocardiographic changes related to hypokalemia have been described in 
literature(23). The earliest change is a decrease in the amplitude of T-wave. As 
potassium level drops further, ST-segment depression and T-wave inversions as well 
as prolongation of PR interval and increase in the amplitude of P wave are seen. The 
U wave is best seen in the mid precordial leads (e.g., V2, V3). Prolongation of QU 
interval with an absent T wave (pseudo QT prolongation) may also be seen. Various 
arrhythmias can occur, mainly tachyarrhythmias and rarely, atrioventricular block. 
The mainstay for the treatment for hypokalemia is replacement of potassium. 
However, care should be taken not to overcorrect. In fact, overcorrection is the most 
common reason for severe hyperkalemia in hospitalized patients(24). This problem is 
maximum with usage of intravenous potassium. Hence, the same should be avoided as 
much as possible.  Routes by which potassium can be used are intravenous (mainly for 
severe hypokalemia) or oral (for mild to moderate hypoklaemia). Intravenous doses 
should not be given more than 20 meq per hour (0.75 gram per hour)(2).  Usually, 
decrease in the serum potassium by 0.3 meq per litre implies a total deficit of 100 
meq(2). Therefore, for a patient with serum potassium of 2.6 meq per litre , at least 
300 meq of potassium is needed for correcting the deficit. However, in calculating the 
deficit, other factors also have to be considered which can independently affect the 
serum potassium like metabolic acidosis. 
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INDIAN EPIDEMIOLOGY 
There are several case reports on the various clinical presentations of hypokalemia, 
including renal tubular acidosis, hyperthyroidism and Conn’s syndrome as the 
etiological causes. However, no prospective observational study on hypokalemia has 
been done so far. 
PATHOGENESIS 
The normal regulation of potassium in the body is brought about by certain important 
hormones. Insulin and catecholamines (beta adrenergic) stimulate Na-K-ATPase 
located on the cell membrane(5). There is a feedback loop which exists in case of 
insulin whereby an increase in potassium leads to insulin secretion and decreased 
potassium inhibition of the same(25,26). Such a kind of mechanism does not exist in 
case of catecholamines (beta adrenergic). It has, however, been seen that the blocking 
of beta receptors leads to hyperkalemia and stimulation of the same leads to 
hypokalemia. This kind of effect is not dependent on the body stores of potassium. 
Thyroid hormone also causes stimulation of the Na-K-ATPase(5). This may lead to 
hypokalemia that is sometimes seen in patients with hyperthyroidism. 
The addition of alkali can lead to the movement of potassium into the cells(27,28). 
The response, however, is variable. This response is very slight in patients with 
chronic kidney disease stage V. 
Aldosterone mainly acts on the kidneys and brings about the excretion of 
potassium(7). It is not clear whether it causes any shift of potassium into the cells. It, 
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just like insulin, also has a feedback loop by which an increase in potassium 
stimulates it’s release and decrease in potassium inhibits it(8,9). 
There are other hormonal as well as non hormonal factors that influence the excretion 
of potassium from the kidneys, but they do not seem to play a part in normal 
potassium homeostasis.  
Table 1: Factors influencing the excretion of potassium in the kidneys 
Increased Potassium Excretion                             Decreased Potassium Excretion                    
Aldosterone                                                                 Absolute aldosterone deficiency or 
Resistance to aldosterone effects 
High sodium delivery to the                                  
Collecting ducts( eg, diuretics) 
Low sodium delivery to the collecting 
duct 
High urine flow(eg, osmotic diuretics) Low urine flow 
High serum potassium levels Low serum potassium levels 
Delivery of negatively charged ions 
to the collecting duct(eg, bicarbonate) 
Renal failure 
 
The following are the pathogenic mechanisms which lead to hypokalemia: 
1) DECREASED INTAKE 
If the potassium in the diet is decreased to less than 1g per day (25 meq per day), there 
is a fall in the serum potassium level since there is no immediate reduction in 
potassium excretion through the kidneys in response to this kind of depletion(29,30). 
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It is rare to see this kind of hypokalemia for which the underlying cause is inadequate 
dietary intake alone(31). Even with starvation or near-starvation, there is depletion of 
potassium stores in the body, but along with this there is breakdown of tissues leading 
to release of potassium which helps to take care of the hypokalemia. 
On ingesting low calorie diets containing a total calorie of 200 to 800 kilocalories per 
day, there can be hypokalemia. This is especially seen if patients do not take 
potassium supplementation or they have an underlying condition which is prone to the 
development of hypokalemia due to loss of potassium through the kidneys like 
primary aldosteronism. Such patients have normal baseline serum potassium (32–34). 
Example for such a kind of diet (mainly have the goal to decrease body weight) which 
have low carbohydrate and high protein is Atkin’s diet. The exact mechanism as to 
why hypokalemia occurs on taking such kinds of diet is not understood fully. One 
mechanism that is thought of is the loss of potassium through its excretion in the 
kidneys. This was because it has been seen that in obese patients there is increased 
loss of potassium through the kidneys for the first two weeks on fasting or eating a 
diet low in carbohydrates(35). The reason for the loss of potassium could be due to 
production of ketone bodies as a consequence of intake of a diet poor in carbohydrate. 
Clay ingestion (also known as geophagia) is a rare cause for hypokalemia. The earliest 
reported case was in 1964 by Mengel and associates(36). The possible mechanism 
postulated was the ability of some clay to bind and trap potassium in the lower 
gastrointestinal tract. They saw a similarity between their patient’s clinical 
presentation and that which has been described more than 150 years back by Cragin 
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and Carpenter as cachexia Africana. Subsequently, there have been several case 
reports describing similar effect of hypokalemia on ingestion of clay(37,38). 
2) INCREASED EXCRETION  
Renal losses 
In this, there is increased excretion of potassium through the kidneys. The 
mechanisms for the same are as follows: 
i) Increased delivery of sodium to the collecting duct( eg, with diuretics, 
osmotic diuresis, salt wasting nephropathies) 
Diuretics 
One of the most common drugs causing hypokalemia is diuretics, mainly the thiazide 
and the loop diuretics. However, it must be remembered that any diuretic that has its 
action at a site which comes before the potassium secretion site can cause 
hypokalemia. This includes carbonic anhydrase inhibitors like acetazolamide along 
with thiazide and loop diuretics. Thiazides and loop diuretics act by chloride-
associated sodium reabsorption, thiazides acting on the distal convulated tubule and 
the loop diuretics acting mainly on the loop of henle and also on the proximal and 
distal convulated tubules. This leads to increased sodium entry into the collecting 
tubules where the same gets reabsorbed forming a suitable electrochemical gradient 
for potassium secretion(9). Additionally, diuretics also cause secondary 
hyperaldosteronism. It is interesting to note that thiazides cause hypokalemia to a 
greater extent than do the loop diuretics despite the fact that they have a lesser 
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natriuretic effect. This may be secondary to decrease in the calcium excretion caused 
by thiazide whereas the loop diuretics cause the opposite effect(39). Therefore, in case 
of loop diuretics, the amount of the luminal calcium in the tubules is increased, which 
inhibits the ENaC channels in the principal cells. This in turn decreases the luminal 
negative potential difference leading to an increase in the excretion of potassium. 
Some of the features seen in the usage of diuretics is as follows: 
a) The dose and degree of hypokalemia are directly related to each other in case 
of thiazide diuretics(40,41). The severity is much more when sodium in the diet 
is increased. Hence, with lower doses, hypokalemia is less common. This is the 
reason why there is increased usage of thiazides in lower doses ( 12.5 to 25 mg 
per day of either chlorthalidone or hydrochlorthiazide) for treating patients with 
hypertension as , at the said doses,  they are effective in controlling elevated 
blood pressures with much less effect on the electrolytes(42) . There were two 
large trials done to see the effect of chlorthalidone on hypertension(43,44). 
These trials showed that in such patients the occurance of hypokalemia which 
needed treatment was about 7 to 8 percentage. Also in stable patients (who 
have been on a fixed diuretic dose), the loss of potassium occurs in the first two 
weeks of starting treatment. Thereafter, there is formation of a new steady 
state. It is thus important to note that a patient, who has been stable with a 
serum potassium within the normal range for about three weeks after initiation 
of a diuretic, is not at a danger of developing a late onset hypokalemia (unless 
there is an increase in the dose of the diuretic or an increase in extrarenal losses 
or there is a decrease in the amount of potassium ingested in diet). Unless the 
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latter happen, there is no necessity of further follow up of serum potassium in 
such patients once a steady state has been established. Perchance a patient on 
diuretic therapy for hypertension develops hypokalemia, then an alternative 
drug needs to be started or there should be an addition of a potassium sparing 
diuretic to treat the hypokalemia or supplementation of potassium needs to be 
done. 
b) Combining furosemide or bumetanide with metolazone almost always leads to 
a decrease in the serum potassium concentration (moderate to severe) even if 
potassium is supplemented(45). 
c) Hypokalemia due to diuretics is often accompanied with metabolic alkalosis. 
Exception to this is acetazolamide which causes metabolic acidosis(45). 
Other drugs 
Amongst other drugs which can cause hypokalemia through the mechanism of 
increasing renal potassium excretion are penicillin and its synthetic derivatives, 
aminoglycoside antibiotics, cisplatin, foscarnet. Penicillin and its derivatives act by 
causing an increased sodium delivery to the distal convulated tubule. The remaining 
drugs cause magnesium depletion and hence, cause hypokalemia(46,47). 
Amphotericin B is another drug which causes hypokalemia by two mechanisms: (i) 
Increased potassium excretion through the kidneys by blocking the secretion of 
hydrogen ions by the kidney. (ii) Causing depletion of magnesium. Laxatives, if given 
in large doses, can cause loss of potassium in faeces. This can cause hypokalemia. 
Similar effects are seen with repeated enemas. 
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Osmotic diuresis 
Patients with uncontrolled diabetes mellitus have an increase in the glucose load to the 
kidneys and hence there is osmotic diuresis due to the same. This leads to an increased 
sodium delivery to the distal tubule which supports potassium excretion. If the 
increased glucose excretion through the kidneys (renal glycosuria) continues for a 
long time, it can lead to a significant depletion of potassium stores in the body(48). 
This kind of hypokalemia is mostly mild or absent, the reason being that both the 
increase in osmolality and the decreased insulin levels prevent shift of potassium from 
the extracellular compartment to the intracellular compartment. In such a situation , 
when insulin is administered , there is accelerated unmasking of the underlying 
hypokalemia, leading unto the development of severe hypokalemia, especially in 
patients who have diabetic ketoacidosis, unless effective measures are taken to replace 
the body stores of potassium simultaneously. 
               ii)    Excess of mineralocorticoids ( eg, primary or secondary 
hyperaldosteronism) 
Mineralocorticoids can be excess in the true sense or there may be a state of apparent 
mineralocorticoid excess. 
Table 2. Mineralocorticoid excess- Causes 
Primary hyperaldosteronism (Aldosterone producing adenomas) 
Primary or unilateral adrenal hyperplasia 
Idiopathic hyperaldosteronism due to 
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A) Bilateral adrenal hyperplasia  
B) Adrenal carcinoma 
Familial hyperaldosteronism (FH-I,FH-II,Congenital adrenal hyperplasias) 
 
Secondary hyperaldosteronism (malignant hypertension, renal secreting tumors, 
hypovolemia) 
Cushing’s Syndrome 
Bartter’s syndrome 
Gitelman’s syndrome 
 
Table 3.Apparant mineralocorticoid excess- Causes 
11Beta-Dehydrogenase-2- Genetic deficiency (syndrome of apparent 
mineralocorticoid excess) 
Inhibition of 11Beta-Dehydrogenase-2 by 
a) glycyrrhetinic/glycyrrhizinic acid and/or carbenoxolone 
b) licorice 
c) food products 
d) drugs 
Liddle’s syndrome 
 
Aldosterone acts on the ENaC channels located on the principal cells of the collecting 
duct by a number of synergistic mechanisms and causes its activation(7,39). This 
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causes an increase in the driving force for potassium excretion leading on to 
hypokalemia. 
Primary and Secondary hyperaldosteronism: 
Increases in aldosterone level in the circulation could either be primary or secondary. 
In seconday hyperaldosteronism, there in an increase in the level of circulating renin 
which in turn leads to an increase in the level of angiotensin II(AT-II) and hence 
aldosterone. The most common cause of  secondary hyperaldosteronism is renal artery 
stenosis(39). Most of the patients with primary hyperaldosteronism have a normal 
serum potassium level(49). This occurs because of the fact that the potassium 
excreting action of aldosterone is countered by the potassium retaining action of 
hypokalemia. Usually, in these patients, the potassium level falls only if there is an 
addition of another inciting agent like a diuretic.  
The causes of primary aldosteronism can be genetic or acquired.  
Genetic 
In congenital adrenal hyperplasia, there are problems in either steroid 11-hydroxylase 
or steroid 17-hydroxylase. The hypertension and hypokalemia which occur in such 
patients are due to increase in the blood level of 11- deoxycorticosterone. 
Isolated primary hyperaldosteronism occurs in two major forms: 
a) Familial hyperaldosteronism type I(also known as glucocorticoid remediable 
hyperaldosteronism). 
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b) Familial hyperaldosteronism type II where aldosterone production cannot be 
suppressed by glucocorticoid administration. 
FH-I is caused by a chimeric gene duplication between the homologous 11-
hydroxylase (CYP11B1) and aldosterone synthase (CYP11B2) genes. 
Aquired 
Acquired causes are: 
Aldosterone-producing adenomas 
Primary or unilateral adrenal hyperplasia 
Idiopathic hyperaldosteronism due to bilateral adrenal hyperplasia 
Adrenal carcinoma 
Amongst these, aldosterone producing adenomas and idiopathic hyperaldosteronism 
are the most common causes ( account for about 60% and 40% of diagnosed cases of 
hyperaldosteronism respectively)(39) 
Cortisol (a glucocorticoid) has affinity for the mineralocorticoid receptor(MLR) equal 
to that of aldosterone.. Hence, it has additional mineralocorticoid like activity. This 
effect, however, does not occur in the cells of distal nephron which are aldosterone 
sensitive. Such a kind of sparing of the distal cells from this action of cortisol is due to 
the enzyme 11-hydroxysteroid dehydrogenase-2, which changes cortisol to 
cortisone(50,51). Genetic mutations in the 11HSD-2 gene therefore leads to cortisol-
dependent activation of MLR and hence the syndrome of apparent mineralocorticoid 
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excess. In this syndrome, there is hypertension, hypokalemia, hypercalciuria and 
metabolic alkalosis(52). The plasma renin activity and aldosterone are suppressed. 
There can be various substances which lead to similar syndrome by blocking of 11 
Hydroxysteroid dehydrogenase-2 enzyme(53). These substances include 
glycyrrhetinic/glycyrrhizinic acid and/or carbenoxolone. Glycyrrhizinic acid is a 
sweetner (natural) found in licorice root.  
Hypokalemia also occurs secondary to increased glucocorticoids in the circulation. 
The incidence of hypokalemia in Cushing’s syndrome due to increase in pituitary 
ACTH is 9 %, but in those where the underlying cause is an ectopic secretion of 
ACTH, it is 50%(54). There are indirect evidences which show that there is decreased 
in the action of  11- Hydroxysteroid dehydrogenase-2 in patients who have ectopic 
production of ACTH. 
In Primary hyperaldosteronism and Cushing’s syndrome, there is chloride resistant 
metabolic alkalosis(55). 
Heriditary hypokalemic alkalosis can be caused by the loss of the transport functions 
of the loop of henle( thick ascending limb) as well as the distal convulated tubule(56). 
Examples for these are Bartter’s and Gitelman’s syndrome.In case of  Bartter’s 
syndrome, thick ascending limb of the loop of henle is affected(five genes are 
involved)  whereas in Gitelman’s syndrome, the distal convulated tubule is 
affected(loss of function mutations in the thiazide-sensitive Na+,Cl- cotransporter 
located in distal convulated tubule). There is occurance of  metabolic alkalosis and 
hypokalemia without hypertension in both theses genetic syndromes. Bartter has an 
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effect similar to the chronic usage of loop diuretics; Gitelman has an effect similar to 
the chronic usage of thiazide diuretics. 
In Liddle's syndrome [genetic activation of epithelial Na+ channels (ENaC)], there 
may be hypokalemia due to an apparent minerolocorticoid excess(57). This is an 
autosomal dominant disorder in which there is gain of function mutation in the sodium 
channels. In this syndrome there is metabolic alkalosis and hypokalemia along with 
hypertension which is similar to 11 Beta-hydroxysteroid dehydrogenase deficiency. 
Drugs with mineralocorticoid or glucocorticoid effects 
Oral mineralocorticoid, fludrocortisone, causes the excretion of potassium through the 
kidneys. Therefore, if this drug is used inappropriately, then it can lead to loss of 
potassium from the body and clinical manifestations of hypokalemia. On the other 
hand, glucocorticoids do not directly influence the secretion of  potassium in the 
kidneys , but they do increase the excretion of potassium through mechanisms which 
are not specific(28). They effect the glomerular filtration rate and the amount of 
sodium moving to the distal convulated tubule. However, long term usage of these 
drugs produce only a minimal decrease in the serum potassium concentration. There 
are other drugs like Gossypol, carbenoxolone, and licorice which inhibit the activity of 
11 Beta-hydroxysteroid dehydrogenase, leading to hypokalemia(58,59). 
iii) Increased urine flow (e.g., osmotic diuretics) 
Osmotic diuretics (like mannitol) mainly cause hypokalemia by increasing the distal 
tubular flow(60). 
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iv) Metabolic acidosis 
One of the cardinal manifestations of type I or classic distal renal tubular acidosis is 
hypokalemia. The amount of hypokalemia in this disorder mainly reflects intake of 
sodium and potassium in the diet and the concentration of aldosterone in the blood. It 
does not directly correlate with the amount of acidosis. If a patient with distal renal 
tubular acidosis is left untreated, then it can lead unto severe hypokalemia which can 
be life threatening. Treatment with sodium bicarbonate corrects the hypokalemia(61), 
but these patients usually need to be on supplementary potassium for long period of 
time(62). In contrast, in patients with proximal or Type II renal tubular acidosis, 
hypokalemia occurs only occasionally in patients who have not been treated. It often 
develops when these patients have been given sodium bicarbonate(63). 
v) Magnesium depletion and Hypokalemia 
Fall in magnesium levels in the blood can lead unto hypokalemia and renal potassium 
wasting(47). The decrease in the level of magnesium in the blood can be due to either 
decreased dietary intake or by abnormal losses. At times of magnesium depletion, the 
intracellular level of potassium gets reduced due to inactivity of the Na+-K+ATPase 
pump. However, the mechanism by which the decrease in magnesium level leads to 
wasting of potassium through the kidneys is unclear. Many a times, the deficiency of 
magnesium and potassium may be coexisting in a patient. The cause may be drugs or 
diseases in which there is loss of both these electrolytes. This makes it complex and 
difficult to know whether the decrease in the serum potassium is an independent 
problem or is due to decrease in magnesium(47). 
28 
 
vi) Others 
Some haematological malignancies can cause severe and refractory hypokalemia, 
namely, acute myelogenous, monomyeloblastic and lymphoblastic leukemias(64,65). 
In these disorders, there is increased loss of potassium through the kidneys. The 
reason as to why this kind of loss occurs is not known. It is also seen that once there is 
remission of these disorders, the hypokalemia also settles. 
Salt wasting nephropathies: Diseases of the kidney where there is a defect in the 
function of the proximal convulated tubule or the loop of henle or the distal 
convulated tubule( affection of distal reabsorption of sodium) can many a times lead 
to hypokalemia. The underlying mechanism is like that which is caused by the effect 
of diuretics. Some examples of disorders producing this kind of effect are Bartter 
syndrome, Gitelman syndrome, tubulointerstial diseases( like reflux nephropathy, 
interstitial nephritis in Sjogren’s ). Others are hypercalcemia, injury to the tubules by 
medications like cisplatin as well as that by lysozyme in leukemic patients as 
described above(17,66,67). 
 
Gastrointestinal losses 
Gastrointestinal losses( eg, diarrhoea, vomiting, nasogastric  suctioning) are common 
causes of  hypokalemia 
Upper Gastrointestinal losses: 
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The amount of potassium contained in the gastric fluid is 5 to 10 meq per litre. 
Therefore, the decrease in potassium that occurs due to these causes is mainly due to 
increased excretion from the kidney(68). Vomiting and nasogastric drainage cause 
metabolic alkalosis (due to selective chloride depletion) and increase in the level of 
bicarbonate in the blood. These in turn cause an increase in the bicarbonate that is 
filtered more than that is reabsorbed. Therefore, an increased amount of bicarbonate 
along with water is carried to the distal tubule. Along with this, vomiting also causes a 
decrease in the plasma volume which leads to an increase in the plasma renin activity 
and hence, an increased aldosterone secretion thereby causing an increased amount of 
potassium to be excreted from the kidney. In order to check for the presence of 
decrease in plasma volume, the urine chloride value is checked which is low. This is 
the chloride sensitive form of metabolic alkalosis. In such cases, repletion of chloride 
through exogenous means helps in the correction of the metabolic alkalosis and 
therefore allows for the restoring of the body stores of potassium. However, the 
dietary intake of potassium should be adequate in such situations. 
This kind of loss of potassium through the kidneys that is seen in patients who have 
loss of gastric fluid is maximally seen in the first few days. After this, the capacity for 
reabsorption of bicarbonate is increased which leads to a significant decrease in the 
amount of sodium, bicarbonate and potassium lost in urine(68). There a decrease in 
the urinary pH from more than 7 to less than 6. 
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Lower Gastrointestinal Losses: 
The amount of potassium contained in the lower gastrointestinal tract fluid is 
comparatively higher than that contained in the upper gastrointestinal fluid ( as high as 
20 to 50 meq per litre). In these kind of losses, there is wasting of bicarbonate and 
metabolic alkalosis with increased levels of chloride( hyperchloremic metabolic 
alkalosis). It is to note here that there may also be hypokalemia which is caused due to 
factitious diarrhoea or the abuse of laxatives. These patients develop metabolic 
alkalosis through a mechanism which is not known. 
At an average, the amount of potassium that is taken in diet is about 80 meq per day. 
If there is hypokalemia, then the amount of fall in the excretion of potassium through 
urine should be 15 to 25 meq per day(68). The normal amount of potassium that gets 
excreted in stool is about 10 meq per day. This amount must go beyond 55 to 65 meq 
per day for the serum potassium to fall and for the patient to become hypokalemic. 
Interestingly, many patients who have diarrhoea and become hypokalemic have a 
level of potassium in the stool not beyond but below this level. This implies that other 
factors also have a part to play in the decrease of the serum potassium like a decrease 
in the oral intake and a decrease in the plasma volume leading to increased activity of 
aldosterone(69). Whenever there is diarrhoea, the volume of faeces increases which in 
turn leads to significant amount of potassium depletion and hence hypokalemia. 
Hypokalemia that occurs due to the loss from the lower gastrointestinal tract usually 
occur when the same occur over a very long period of time. Examples for prolonged 
diarrhoea are that occurring with villous adenoma, a VIPoma( Vasoactive Intestinal 
31 
 
peptide secreting tumor), infectious diarrhoea which are persistent (69–71). 
Hypokalemia due to lower gastrointestinal losses is especially important in tropical 
infective conditions like malaria and leptospirosis. 
There are some other causes in which there is loss of potassium through the lower 
gastrointestinal tract. These are: 
a) Colonoscopy preparation: While preparing the bowel for colonoscopy with 
agents like sodium phosphate, polyethylene-glycol based preparations( 
especially in elderly individuals) (72,73) 
b) Ogilvie’s syndrome: Otherwise known as colonic pseudoobstruction has 
secretory diarrhoea as its clinical manifestation. In this there is an increased 
potassium in the faeces due to stimulation of the secretion of potassium in the 
colon. 
 
Sweat 
Excretory losses of potassium can also occur through sweating. A study conducted in 
2001 showed that among soccer team players in a high school (while they were 
actively training), the mean amount of iodine, sodium, potassium and calcium lost in 
sweat were 52 microgram,1.896 microgram, 248 mg, and 20 mg respectively(74). 
Loss of potassium in the sweat daily is normally very minimal and insignificant. The 
concentration of potassium in sweat per day is about 5 to 10 meq per litre only, but , in 
people who are working in a hot environment or climatic conditions the production of 
sweat goes more than or equal to 10 litres per day. This can lead to the loss in 
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potassium stores if replacement is not done. A lot of potassium loss through sweat can 
also be a manifestation of cystic fibrosis(75). One more factor which may add to the 
potassium loss is the exercise induced stimulation of the release of aldosterone  
leading unto increased loss of potassium through excretion in the kidneys(74,76). 
 
3) EXTRACELLULAR OR INTRACELLULAR SHIFT 
Often this mechanism occurs along with increased excretion of potassium through the 
kidneys, which leads to an incremented effect on the loss of potassium. Many a times, 
the intracellular shifts are episodic. Frequently, they are self-limited (e.g., acute 
insulin treatment for hyperglycemia ).Whatever be the cause for hypokalemia, it 
produces similar signs and symptoms. Since potassium is an intracellular cation(3) 
and a huge number of factors can influence the actual serum potassium concentration, 
there can be significant loss of potassium without exhibiting frank hypokalemia. This 
can be seen in patients with diabetic ketoacidosis where there is significant potassium 
deficit, but the serum potassium in such patients is rarely low and many a times is 
frankly elevated(77). 
On the other hand, hypokalemia may not always be a representation of a true deficit in 
the body’s total potassium stores. For example, on administering insulin acutely, it can 
push potassium transiently into the cells, leading unto hypokalemia for a short while 
but this does not indicate potassium depletion(45). 
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TRANSCELLULAR SHIFTS-DRUG INDUCED 
Beta2-Sympathomimetic Drugs 
Examples of Beta2 adrenergic agonists are: 
Epinephrine 
Decongesants like Pseudoephedrine and phenylpropanolamine 
Bronchodilaters like albuterol, terbutaline, pirbuterol, isoetharine, fenoterol, 
ephedrine, isoproterenol, metaproterenol  
Tocolytic agents like ritodrine, nylidrin 
It has been seen that the reduction in seum potassium by a standard dose of  albuterol 
(nebulized) is about 0.2 to 0.4 meq per liter. On repeating the dose after 1 hour, the 
reduction is by about 1 meq per liter(78,79).  The effect lasts for about four hours. 
Similarly, ritodrine and terbutaline, on being administered intravenously for 4 to 6 
hours, can lead to a decrease in serum potassium to as much as 2.5 mmol per liter(80). 
Pseudoephredine overdose can also lead to severe hypokalemia(81).  
There also have been case reports which have described hypokalemia in patients due 
to exposure to heroin or meat products that have been mixed with 
sympathomimmetic( beta agonist)  agents like clenbuterol(82) 
Whatever be the underlying reason for increased beta adrenergic stimulation, the 
amount of hypokalemia will be more in those patients who already have decreased 
serum potassium due to causes like diuretics(83). 
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When is it that the hypokalemia induced by the administration of beta stimulators 
likely to produce arrhythmias? This may be seen in the following instances: 
- On administering along with a diuretic simultaneously in hypertensive 
individuals(84). 
- In pregnant women who have preterm labour(85) 
Theophylline and other Xanthines 
There are two mechanisms by which theophylline and other xanthines and caffeine 
act(86). Firstly, they cause a stimulation of the release of sympathetic amines. 
Secondly, they inhibit cellular phosphodiesterase leading to an increase in the activity 
of Na-K-ATPase activity. Acute toxicity with theophylline leads to severe 
hypokalemia(86,87). Caffeine content in a few drops of coffee brings down the serum 
potassium by about 0.4 meq per liter(88). 
Other drugs 
CALCIUM CHANNEL BLOKERS 
Calcium channel blockers, at usual doses, do not influence the serum potassium 
concentration. If, however, overdose occurs with verapamil, it leads to severe 
hypokalemia by increasing the entry of potassium into the cells(89). 
INSULIN 
Insulin causes potassium to move from the extracellular space to intracellular space. It 
always causes a transient decrease in the serum potassium concentration. Therefore, 
the decrease in serum potassium caused by insulin is not a major clinical problem 
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except during times of overdose(86) or while diabetic ketoacidosis is being managed. 
This hormone brings about the movement of potassium into the skeletal muscle cells 
and hepatocytes. Its action is mainly on the Na-K-ATPase pump(90), whereby its 
activity is increased leading to the entry of potassium into the cells. This kind of effect 
due to insulin is most prominently seen on administration of insulin exogenously( for 
example, in patients with diabetic ketoacidosis or severe hyperosmolar non ketotic 
hyperglycemia- these patients are many a times normokalemic when they initially 
come to the hospital even though there would have been depletion of potassium in 
them)(77). Insulin overdose can rarely cause hypokalemia(86).  
On intake of an increased amount of carbohydrate in the diet, there is release of 
endogenous insulin which can lead on to hypokalemia( for example, as can be seen in 
refeeding syndrome(91) and after giving intravenous potassium in an intravenous fluid 
containing dextrose solution in water) 
CHLOROQUINE INTOXICATION 
One common feature in patients with acute poisoning/overdose with chloroquine is 
that the serum potassium level falls less than 2 meq per litre(86). The mechanism of 
this kind of effect of chloroquine is possibly due to the movement of potassium into 
the cells and the same can be amplified if epinephrine is used to treat the toxicity. 
Also it inhibits the movement of potassium out of the cells. 
CESIUM  INTOXICATION 
Most of the times, intoxication with caesium occurs as a result of the usage of cesium 
chloride an an alternative treatment for cancer. This can cause hypokalemia(92). The 
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reason as to why this occurs is not clear, but could be due to the blocking of the 
potassium channels located in the cell membrane by cesium(93). 
ANTIPSYCHOTIC DRUGS 
Certain antipsychotic drugs like resperidone and quetiapine can cause hypokalemia. 
But this is a rare adverse effect(94,95). 
 
TRANSCELLULAR SHIFTS- NONDRUG RELATED 
Elevated extraxellular pH 
There can be two situations in which there is elevated pH, metabolic alkalosis and 
repiratory alkalosis. Such conditions can lead to the entry of potassium from the 
extracellular compartment to the intracellular compartment. The reason as to why this 
kind of movement occurs is that whenever there is an alkalosis, there is movement of 
hydrogen ions out of the cells. Hence, to maintain a state of electrical neutrality, it is 
necessary for some potassium ions ( as well as sodium ions) into the cell. The fall in 
serum potassium for every 0.1 unit rise in pH is 0.4 meq per litre(96). 
It must however be remembered that though alkalemia causes hypokalemia by 
transcellular shift, it is common to find metabolic alkalosis in hypokalemia. The 
reason for this is that the prime causes of hypokalemia( for example diuretics, 
vomiting, hyperaldosteronism) also cause a movement of hydrogen ions out of the 
cell.  
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Decreased serum potassium also brings about the reabsorption of bicarbonate and 
hence, hypokalemia is important as a cofactor in maintaining metabolic alkalosis, thus 
causing an impairment of the rectification of the alkalemia by the renal clearance of 
the increased bicarbonate. 
Hyperthyroidism related 
Moderate to severe hypokalemia (serum potassium< 3.0 meq per liter) can rarely 
occur in patients with hyperthyroidism(97). The manifestation of the same may be 
muscle weakness and paralysis. This can be of sudden onset and severe. People of 
Asian origin have an increased chance of developing this kind of symptom. It occurs 
in about 2 to 8 percent of Asian patients with hyperthyroidism. Despite the fact that 
there is increased occurance of thyrotoxicosis in women, men, especially those of 
Asian origin, are more likely to manifest this complication. The manifestations of an 
attack of thyrotoxic periodic paralysis resemble those of primary Hypokalemic 
periodic paralysis. These episodes settle with treatment of the underlying 
hyperthyroidism. The muscle weakness can be episodic and acute. The clinical 
features of hyperthyroidism usually occurs along with these episodes, though may be 
subtle. These episodes have a rapid improvement on replacement of potassium. 
Hypokalemic periodic paralyses- Familial 
This is a rare autosomal dominant disease with incomplete penetrance. This disorder 
is caused due to mutations in one of the two genes(98,99): 
a) voltage-sensitive skeletal muscle calcium channel gene, CALCL1A3 – 
Hypokalemic Periodic Paralysis type 1 
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b) voltage sensitive sodium channel gene SCN4A- Hypokalemic Periodic 
Paralysis type 2 
Hypokalemic periodic paralysis Type 1 accounts for 90 % of cases and Hypokalemic 
periodic paralysis type 2 is responsible for 10% of cases(39). These mutations lead to 
the generation of an aberrant gating pore current which makes the muscle cell to 
depolararize whenever there is hypokalemia.The usual age of onset is adolescence. 
Gender difference is seen in terms of men being more often affected than women as 
there is decreased penetrance in the female gender. Episodic sudden attacks of muscle 
weakness occur with a low serum potassium concentration, many a times less than 2.5 
meq per liter. Such episodic attacks with the age of onset being more than 25 years 
almost never has periodic paralysis as the underlying aetiology the exception being 
that of thyrotoxic periodic paralysis. Various factors are there which can trigger an 
attack, including high intake of carbohydrates or sodium and physical exertion. These 
inciting events are accompanied with an increased release of epinephrine or insulin ( 
both of which are responsible for causing transcellular shift of potassium into the cell 
and hypokalemia)(100). The clinical finding that may be seen in these patients is that 
there is weakness of the proximal group of limb muscles much more than the distal 
muscles. The muscles which are less likely to be involved are the ocular and bulbar 
muscles. The muscles that assist in respiration are usually not involved but, perchance, 
they do get involved, the patient may die. These attacks usually get better within 
twenty four hours. During times of attack, there may be development of cardiac 
arrhythmias that can be life threatening. One late complication that may happen in 
these patients is the development of severe, lower limb weakness involving the 
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proximal group of muscles which disables the patient. The underlying mechanism for 
hypokalemia is shift of potassium from the extracellular to the intracellular space. The 
finding of a low value of serum potassium during attacks and with the exclusion of the 
other causes helps to establish the diagnosis of hypokalemic periodic paralysis. During 
the interval in between attacks, if a muscle biopsy is taken, it shows single or multiple 
vacuoles which appear at the centre or tubular aggregates. There are provocative tests 
which are available to establish the diagnosis with the usage of glucose and insulin. 
However, these tests are mostly not required. On the other hand, they can be harmful. 
If an electromyography is done during an attack, it shows decreased amplitude. In 
severely weak muscles, the same may show and electrical silence. During the interval 
periods, the electromyography and nerve conduction velocities are normal, except the 
presence of myopathic motor unit action potential in candidates who have fixed 
weakness.  These patients have a low urine potassium excretion which is a 
distinguishing feature from renal causes of hypokalemic paralysis(101). Replacement 
of potassium is often life saving and is indicated for the treatment of attacks. The 
monitoring of the muscle power and electrocardiogram should be done. Usually the 
administration of potassium orally is enough, intravenous therapy is rarely required 
(for e.g., if the patient has any problem with swallowing or if the patient has 
vomiting). Syrup Potassium chloride may be given orally at a dose of 0.2 to 0.4 meq 
per kilogram every half an hour. If intravenous potassium replacement is done, then 
the preferred vehicle for the same is mannitol.  
The long term aim of treatment is to prevent attacks. This is important as it may 
reduce the occurance of fixed weakness which occurs as a delayed complication in 
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such patients(102). Various prophylactic measures have been tried to prevent 
recurrences. The success rates have been variable. These methods include 
administration of spironolactone, triamterene, and acetazolamide(103). It has been 
seen that the prophylactic usage of acetazolamide at a dose of 125 to 1000 mg per day 
in divided doses helps to decrease or may even stop the attacks in hypokalemic 
periodic paralysis type 1. However, the administration of acetazolamide may lead to 
precipitation of an attack in hypokalemic periodic paralysis type 2.A paradoxical 
effect that is seen is further decrease in the serum potassium level. However, this is 
balanced by the beneficial effect of metabolic acidosis. Perchance the attacks persist 
despite acetazolamide, then oral supplementation with potassium chloride should be 
initiated along with acetazolamide therapy. There are some patients who may need 
treatment with triamterine or spironalactone. The doses of both these drugs are same, 
that is, 25 to 100 mg per day . 
Delirium tremens 
In delirium tremens, there is a sudden decrease in the serum potassium concentration 
by about 1.0 meq per liter(104). The decrease in serum potassium is presumed to be 
due to Beta2 adrenergic stimulation leading to movement of potassium from the 
extracellular space to the intracellular space.  
Barium intoxication 
Barium intoxication, either due to intentional or accidental ingestion(105), inhibits the 
shift of potassium from inside the cells to the extracellular space(106). In severe cases, 
there can be weakness and paralysis of muscles and rhabdomyolysis. Vomiting and 
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diarrhoea also occur which have an augmenting effect on the hypokalemia. In this 
poisoning, administration of intravenous potassium should be done as soon as 
possible(106). Another effective therapy is hemodialysis(107). 
Vitamin B12 supplementation and blood transfusion 
Treatment with Vitamin B12, for example, for severe pernicious anemia can lead to 
hypokalemia, the mechanism being increased uptake of potassium be the newly 
formed cells(108). Blood transfusion with washed red cells (previously frozen) can 
lead to hypokalemia due to the same mechanism(109). 
Granulocyte macrophage colony stimulating factor  
Literature also describes the development of hypokalemia in patients receiving 
granulocyte- macrophage colony stimulating factor(110). The underlying mechanism 
is again the shift of potassium from the extracellular compartment to the intracellular 
compartment. There is increased uptake of potassium by the hematopoietic cells. 
Total Parenteral Nutrition 
The administration of total parenteral nutrition leads to the development of various 
forms of electrolyte disturbances. Literature describes the occurance of hypokalemia 
to as much as 3 to 12% of surgical patients who were treated with total parenteral 
nutrition(111). 
Hypothermia 
Hypothermia can be either a presenting problem or it can be induced( as part of 
therapeutic hypothermia post cardiac arrest). Whatever be the underlying reason for 
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hypothermia, it can lead to a decrease in the circulating level of potassium(112). The 
mechanism for the same is transcellular shift of potassium from the extracellular 
compartment to the intracellular compartment rather than a loss. It is of importance 
that once should anticipate this electrolyte abnormality when a patient is hypothermic 
and prompt initiation of treatment for the same is indicated else it may progress unto 
severe hypokalemia and its consequences. 
Pseudohypokalemia 
Pseudohypokalemia or factitious hypokalemia is a term which is used to describe low 
biochemical values of serum potassium when the actual serum potassium in a patient 
is normal. This kind of effect is mainly seen in patients who have a high whole blood 
cell count (>100000 per microlitre) when the blood samples have been kept in room 
temperature for some time(113). Such a scenario is encountered in patients with acute 
leukemia. This kind of effect happens due to the movement of potassium into the 
leukemic cells. Factitious hypokalemia should not, however, be confused with true 
hypokalemia which occurs in patients with acute myeloid leukemia(especially the one 
with monocytic differentiation)(64). In the latter, the reason for hypokalemia is 
increased renal excretion of lysozymes which increases the excretion of potassium 
from the tubules. 
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JUSTIFICATION 
This study is being done in order to check the occurance of the causes of  hypokalemia  
in an Indian hospital setting. Hypokalemia can be detrimental as it can lead to cardiac 
arrhythmias and death. It is not only important for it to be detected and treated, but 
identification of the underlying cause is also equally necessary as catching that may 
provide long term solution to prevent recurrences of the former. How this electrolyte 
abnormality presents or the factors affecting it in an Indian setting is not known. 
Therefore, this study is being done to determine the same. It is also being done in 
order to see if there is any relationship between the dose and duration of treatment of 
hypokalemia and its severity 
METHODS 
The study proposal was approved by the Institutional Review Board on 15/01/2015. 
STUDY DESIGN 
The study was conducted in a tertiary care hospital, Christian Medical College and 
Hospital, Vellore, Tamil Nadu, South India, which is a 2062 bedded hospital. It was a 
prospective observational study with the aims and objectives as stated above.  The 
patients were recruited from the medical wards being managed by the internal medical 
units in the institution. There are five such units who admit patients in four different 
wards. Prior to starting the study a retrospective pilot study was done in order to 
determine the sample size. In this retrospective study the proportion of patients 
admitted to the medical wards who had hypokalemia on the first day of admission 
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over a period of one year from  April 2013 to March 2014 was calculated and a 
sample size of 200 was obtained. 
The recruitment of patients began from March 1
st
 2015. The definition of hypokalemia 
based on literature and standard reference values was taken as a serum potassium of 
less than 3.5 meq per litre. Every consecutive patient with hypokalemia on day 1 of 
admisssion was recruited into the study. The controls were selected as every tenth 
consecutive patient who had serum potassium of more than or equal to 3.5 meq per 
litre. Consecutive recruitment was done based on the time of admission to the medical 
ward after taking a written informed consent. The same was determined by means of 
checking the inpatient chart of the patient which had the time of admission printed on 
it. The total number of cases was 181 and the total number of controls was 20. Post 
recruitment the data for each of the patient as well as control was collected. The data 
consisted of demographic profile, comorbidities, usage of any inciting agents in the 
past 3 months, the symptoms and signs that the patient had, electrocardiographic 
changes if the same had been taken and relevant laboratory investigations along with 
the final outcome in terms of discharge or death, the final primary diagnosis and the 
possible underlying cause. The demographic profile comprised the name of the 
patient, gender, the hospital number of the patient, the date of admission, the date of 
discharge, the occupation of the patient, the medicine unit admitting the patient,the 
state or the country (if the patient is from a country other than India) to which the 
patient belongs to, his address and communication number. Among the comorbidities, 
the data was collected for diabetes mellitus, hypertension, smoking, alcohol, ischemic 
heart disease, cerebrovascular accident, heart failure, peripheral vascular disease, 
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chronic obstructive pulmonary disease, chronic kidney disease , liver disease, 
dementia, lymphoma and any other comorbidity. The number of years of having the 
comorbidity was also noted. Data for the inciting agents used in the last three months 
prior to admission were mainly for loop diuretics or thiazide diuretics( if the patient 
was on these, the specific name was also required to be mentioned), usage of steroids 
in any form, inhaled beta-2 agonists, amphotericin B/azoles or echinocandins 
specifying the name, cytotoxic agents like cisplatin, hydrxycobalamine, 
theophylline/aminophylline or caffeine, digoxin, overdoses of quetiapine or 
verapamil. The recruitment was done till May 31
st
 2015 when the sample size was 
reached. 
After recruitment, all the patients were followed up till discharge or death. The data 
that were collected during the time of follow up were the final outcome in terms of 
either discharge or death, the amount of potassium( oral, intravenous and both) used 
for correction of potassium in grams and the duration to achieve a normal serum 
potassium value of 3.5 to 4.5 meq per litre. For oral correction each 15 ml of syrup 
potassium chloride contains 1.5 grams of potassium. Based on this further calculation 
of the oral dose in grams was done. The data for both oral and intravenous corrections 
was obtained from the treatment charts of the patient during the time of hospital stay. 
After obtaining the above information, the data was analysed Thereafter results were 
obtained and conclusions drawn from the same. 
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                                                               Flow of patients 
                                                         Patients in Medicine Wards  
                                                                Total 201 patients 
 
 
                                                             Every 10
th
 case a control 
  
 
                                 Cases                                                                      Control 
                                   181                                                                            20 
 
 
                                  Demographic profile,Lab Ix,amount&duration of K+ 
 
 
                                                           Mild, Moderate,Severe 
 
 
                                                     Follow up till discharge/death 
 
a) Proportion of patients with hypokalemia at admission and it’s causes  
b) Association of hypokalemia with mortality in comparision to eukalemic 
controls 
c) Any observation in relationship of hypokalemia with comorbidities 
d) Correlation of ECG changes with severity of hypokalemia 
e) Dose and duration of potassium required for correction in each severity class 
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PATIENT POPULATION: 
The patient population consisted of patients admitted in the medical wards with an 
admission potassium value of less than 3.5 meq per litre who fit into the inclusion 
criteria and gave a written informed consent. The consent was taken in a language that 
the patient was able to understand. 
 
INCLUSION CRITERIA: 
The following were the criteria for inclusion into the study: 
(1) All patients admitted in the medical wards with hypokalemia at admission  
                 defined as a serum potassium of less than 3.5 meq/L 
(2) Age more than or equal to 18 years 
 
EXCLUSION CRITERIA: 
There was only one exclusion criteria: 
(1) Age less than 18 years 
 
DEFINITIONS: 
Mild hypokalemia: Serum potassium 3.0 to 3.49 meq per litre 
Moderate hypokalemia: Serum potassium 2.50 to 2.99 meq per litre 
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Severe hypokalemia: Serum potassium less than or equal to 2.49 meq per litre 
Normal potassium range: Serum potassium 3.50 to 4.50 meq per litre 
 
INTERVENTION: 
Since this is an observational study, no intervention was done. 
 
CASES:  
Any patient with serum potassium level of less than 3.5 meq per litre (excluding the 
value of 3.5 meq per litre) at day 1 of hospital admission 
 
CONTROL: 
The control group comprised patients who had a serum potassium value of more than 
or equal to 3.5 meq per litre. Every tenth consecutive patient admitted to the medical 
wards was taken as a control. There were 20 such controls. 
 
OUTCOME: 
The outcomes that were being studied were the following: 
1. To find the proportion of patients of hypokalemia and its 
causes in adult medical wards. 
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2. The dose and duration of potassium( intravenous or oral or 
both)  required for correction 
3. Correlation of hypokalemia with mortality 
4. Association of hypokalemia with other comorbidities 
5. Association of ECG changes with severity of hypokalemia 
 
THE INTERVIEW AND CONSENT: 
All patients and controls who fulfilled the eligibility criteria were approached and 
were initially explained verbally about the study and that we wished to get their 
consent for the same. They were then given a written information sheet in a language 
which they could understand and were asked to read the same. If they had any doubts, 
the same was clarified. Thereafter, if they agreed to be included in the study, they 
were asked to sign a written consent in a language which they could understand.  
 
THE DATA: 
The data for demographic profile, comorbidities, use of inciting agents, symptoms and 
signs, were taken from the history sheet. The relevant laboratory data was taken from 
the patient’s laboratory record. The amount and duration of potassium required for 
correction was calculated from the patient’s treatment record. Data for the final 
outcome and final primary diagnosis was obtained from the discharge or the death 
summary of the patient. The possible underlying cause was determined by means of a 
checklist obtained from the causes of hypokalemia as mentioned in Harrison’s 
Principles of Internal Medicne, 18
th
 edition. In case a cause was not mentioned in this 
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list but has been described and known in literature ro cause hypokalemia , it was also 
included as the possible underlying cause. 
DATA ENTRY: 
The data was entered in Epidata version 3.1 and analysis was done using the SPSS 
software. 
 
STATISTICAL ANALYSIS: 
 
 Sample Size 
The sample size to show proportion of patients with hypokalemia was found to be 200 
subjects with 95% confidence intervals and 5% precision with an anticipated 
proportion of about 15% 
(A retrospective pilot analysis was done prior to the calculation of sample size using 
medical records of patients admitted in Christian Medical College and hospital, 
Vellore from 01/04/2013 to 31/03/14 which showed that the total number of adult 
patients admitted in the hospital with hypokalemia on the day of admission was 
15,521; Total adult in patient population during the same time was 1,01,631. Hence, 
the proportion of patients with hypokalemia during this time period was 15.2 %) 
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Outcome measures: 
The proportion of hypokalemia was calculated using the frequency and then expressed 
in percentage. 95% confidence interval for the proportion was calculated. The causes 
of hypokalemia, based on the assessment of the treating physician, were also 
calculated and expressed as percentages.  
The association of hypokalemia and the causes of hypokalemia was assessed using 
chi-square test for categorical variables and independent t-test was used to compare 
the means of continuous variables with the presence or absence of hypokalemia and 
the causes of hypokalemia 
Median time to mortality was compared across the groups using Tarone Ware test. 
Cox Proportional regression was planned to be done to compare the median time 
adjusting for any other factors.  
The variables which were found significant in the chi-square or independent t-test 
were planned to be considered for multivariate analysis by performing logisitic 
regression.  
The risk factors (use of inciting agents) for hypokalemia were also planned to be 
assessed using logistic regression after selecting the variables which were found to be 
significant from bivariate analysis. 
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RESULTS    
Table 4: Demographic characteristics 
 Cases 
(n=181) 
% Control 
(n=20) 
% 
Age (Mean) 50  48  
Age Groups (years) 
18-28 
28-38 
38-48 
48-58 
>58 
 
19 
28 
36 
28 
70 
 
10.5 
15.5 
19.9 
15.5 
38.7 
 
04 
04 
00 
05 
07 
 
20 
20 
00 
25 
35 
Gender 
Male 
Female 
 
110 
71 
 
60.8 
39.2 
 
13 
07 
 
65 
35 
Medicine Unit 
I 
II 
III 
IV 
V 
 
38 
40 
40 
26 
37 
 
21 
22.1 
22.1 
14.4 
20.4 
 
04 
04 
06 
02 
04 
 
20 
20 
30 
10 
20 
Occupation 
Housewife 
 
54 
 
29.8 
 
03 
 
15 
53 
 
Labourer 
Student 
Business 
Farmer 
Others 
53 
07 
18 
21 
28 
29.3 
  3.9 
  9.9 
11.6 
15.5 
 
03 
03 
01 
02 
08 
15 
15 
05 
10 
40 
State 
Tamil Nadu 
Andhra Pradesh 
West Bengal 
Others 
 
121 
  30 
  17 
  13 
 
66.9 
16.6 
  9.4 
  7.2 
 
11 
02 
02 
05 
 
55 
10 
10 
25 
Use of Inciting agents( last 3 
months) 
Loop/Thiazide diuretics 
Steroids 
Inhaled Beta agonists 
AAE 
Insulin 
Antibiotics 
Cytotoxics 
TAC 
Hydroxycobalamine 
Quetiapine overdose 
 
 
16 
15 
07 
00 
13 
13 
01 
09 
00 
00 
 
 
8.8 
8.3 
3.9 
0 
7.2 
7.2 
6.0 
4.9 
0 
0 
 
 
00 
01 
00 
00 
02 
02 
00 
02 
00 
00 
 
 
00 
05 
00 
00 
10 
10 
00 
10 
00 
00 
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Verapamil overdose 00 0 00 00 
 
 
 
 
 
Figure 1:  Proportion of patients among cases and control based on age distribution 
X- axis: Percentage of patients; Y axis: Age distribution in years 
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Figure 2: Bar chart showing the proportion of patients using inciting agents in the last 
3 months among cases and control 
X-axis: Proportion of patients; Y-axis: Inciting agent 
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Table 5: Comorbidities in Cases and Control groups along with their frequencies 
Comorbidity Cases 
 (n=181) 
(%) Control 
(n=20) 
(%) 
Diabetes 
Mellitus 
69 38.1 8 40 
Hypertension 61 33.7 7 35 
Smoking 27 14.9 4 20 
Alcohol 26 14.4 4 20 
Ischemic Heart 
Disease 
13   7.2 1 5 
Cerebrovascular 
Accident 
11   6.1 0 0 
Leukemia   0   0 0 0 
Heart Failure   3   1.7 0 0 
Peripheral 
Vascular 
Disease 
  2   1.1 1 5 
COPD   9   5.0 1 5 
CKD   5   2.8 1 5 
Liver Disease   0   0 0 0 
Dementia   0   0  0 0 
Lymphoma   1   0.6 0 0 
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 Figure 3:  Proportion of co-morbidities in cases and control 
IHD: Ischemic heart disease; CVA: Cerebrovascular accident; PVD: Peripheral 
Vascular Disease; COPD: Chronic obstructive pulmonary disease; CKD: Chronic 
Kidney Disease 
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Table 6: Co morbidities in Cases based on severity of hypokalemia 
 
Comorbidities Mild(n=140) % Moderate(n=30) % Severe(n=11) % 
Diabetes 
Mellitus 
56 40 9 30 4 36.4 
Hypertension 49 35 8 26.7 4 36.4 
Smoking 16 11.4 8 26.7 4 36.4 
Alcohol 22 15.7 3 10 1   9.0 
IHD 11   7.9 2   6.7 0   0 
CVA   8   5.7 3 10 0   0 
Leukemia   0   0 0   0 0   0 
Heart Failure   3   2.1 0   0 0   0 
PVD   1   0.7 0   0 0   0 
COPD   6   4.3 2   6.7 1   9.0 
CKD   4   2.9 0   0 1   9.0 
Liver Disease   1   0.7 0   0 0   0 
Dementia   0   0 0   0 0   0 
Lymphoma   0   0 0   0 1   9.0 
 
IHD: Ischemic heart disease; CVA: Cerebrovascular Accident; PVD: Peripheral 
Vascular disease; COPD: Chronic Obstructive Pulmonary Disease; CKD: Chronic 
Kidney Disease 
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Figure 4:  Co-morbidities in the different classes of severity of hypokalemia expressed 
as percentage 
IHD: Ischemic heart disease; CVA: Cerebrovascular accident; PVD: Peripheral 
Vascular Disease; COPD: Chronic obstructive pulmonary disease; CKD: Chronic 
Kidney Disease 
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Figure 5: Histogram showing the distribution of serum potassium level among cases 
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Figure 6: Histogram showing the distribution of serum potassium among controls 
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PROPORTION OF PATIENTS WITH HYPOKALEMIA 
Table 8: Proportion of patients with hypokalemia 
Number of patients 
in the medical 
wards 
Hypokalemics at 
day 1 of admission 
Proportion(%) 95% Confidence 
Interval 
377 181 48 0.42-0.53 
 
 
 
Figure 7: Proportion of patients admitted with hypokalemia at day 1 of hospital 
admission 
52% 
48% 
Proportion of hypokalemic patients 
Non hypokalemics Hypokalemics 
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Table 9: Proportion of patients based on severity of hypokalemia among the total 
number of patients admitted 
Hypokalemia Proportion(%) 95% Confidence Interval 
Mild  37 0.32-0.42 
Moderate   8 0.05-0.11 
Severe   3 0.01-0.05 
 
 
 
 
 
 
Table 10: Proportion of patients based on severity among patients who had 
hypokalemia 
Severity of hypokalemia Proportion (%) 95% Confidence Interval 
Mild 77.3 0.70-0.83 
Moderate 16.6 0.11-0.22 
Severe 0.06 0.03-0.10 
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Figure 8:  Pie chart showing the number and proportion of patients in accordance to 
the severity of hypokalemia  
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THE UNDERLYING CAUSES FOR HYPOKALEMIA (based on the treating 
physician’s assessment) 
Table 11: Most probable underlying causes for hypokalemia  
Underlying cause Frequency % 
Vomiting   61 33.7 
Loose stools   28 15.5 
Cerebrovascular accident   26 14.4 
Magnesium deficiency   12   6.6 
Diuretics   14   7.7 
Deriphylline     2   1.1 
Distal RTA     1   0.6 
Proximal RTA     2   1.1 
Digoxin     2   1.1 
Mineralocorticoid excess     1   0.6 
Steroids   10   5.5 
Penicillin derivatives     3   1.7 
Insulin   11   6.1 
Metabolic alkalosis     5   2.8 
Osmotic diuresis   13   7.2 
Inhaled Beta agonist     5   2.8 
Chronic kidney disease   21 11.6 
Undetermined 146 80.7 
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Figure 9: The possible underlying causes for hypokalemia at day 1 of hospital 
admission in percentage 
SWN: salt wasting nephropathy; IBA: inhaled beta agonist; RTA: Renal tubular 
acidosis; Mg: Magnesium; CVA: Cerebrovascular accident 
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HYPOKALEMIA AND MORTALITY 
 
Table 12: Mortality among cases and control groups 
   Cases    Control % 
 Mild % Moderate % Severe %   
Discharged 132 94 30 100 10 90.9 19 95 
Death    8   6   0     0   1   9.1   1   5 
 
 
 
Figure 10: Mortality among cases and control 
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Figure 11: Mortality in the various degrees of severity of hypokalemia 
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Table 13: Mortality Rate among cases and control groups 
 Mortality Rate(%) P value 
Cases 4.4 0.631 
Control 0.4 0.631 
 
 
 
Table 14: Mortality Rate among various degrees of severity of hypokalemia 
Severity of Hypokalemia Mortality Rate(%) P value 
Mild 3.9 0.246 
Moderate 0 - 
Severe 0.04 0.246 
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 Figure 12: Survival plot in cases and control (1= cases; 2= control)              
‘Censored’ implies, the ones who were living were followed up till the point of 
discharge and not thereafter. 
 
Table 15: Mean survival time in cases and control 
Category Mean Survival time 
          (Days) 
95 % CI 
Cases 47.65 34.5-60.7 
Control 56.84 49.0-64.6 
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      Figure 13: Survival plot in various groups of severity of hypokalemia ‘Censored’ 
implies, the ones who were living were followed up till the point of discharge and not 
thereafter 
 
Table 16: Mean Survival time in accordance to severity of hypokalemia 
Severity of Hypokalemia Mean Survival time 
        (Days) 
95% CI 
Mild 44.5 29.5-59.5 
Moderate* - - 
Severe 24.0 24.0-24.0 
*Moderate hypokalemics did not have any death 
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HYPOKALEMIA AND COMORBIDITIES 
Table 17: Univariate analysis of hypokalemia and comorbidities in cases and control 
Comorbidity Cases 
 (n=181) 
(%) Control 
(n=20) 
(%) P value 
Diabetes 
Mellitus 
69 38.1 8 40 1.000 
Hypertension 61 33.7 7 35 1.000 
Smoking 27 14.9 4 20 0.521 
Alcohol 26 14.4 4 20 0.050 
Ischemic Heart 
Disease 
13   7.2 1 5 1.000 
Cerebrovascular 
Accident 
11   6.1 0 0 0.605 
Leukemia   0   0 0 0 1.000 
Heart Failure   3   1.7 0 0 1.000 
Peripheral 
Vascular 
Disease 
  2   1.1 1 5 0.271 
COPD   9   5.0 1 5 1.000 
CKD   5   2.8 1 5 1.000 
Liver Disease   0   0 0 0 1.000 
Dementia   0   0  0 0 1.000 
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Lymphoma   1   0.6 0 0 1.000 
IHD: Ischemic heart disease; CVA: Cerebrovascular Accident; PVD: Peripheral 
Vascular disease; COPD: Chronic Obstructive Pulmonary Disease; CKD: Chronic 
Kidney Disease 
 
SEVERITY OF HYPOKALEMIA AND COMORBIDITIES 
Table 18: Univariate analysis of the severity of hypokalemia and comorbidities  
Comorbidity Mild 
n 140 
 % Moderate 
 n 30 
% Severe 
n11 
% P  
Diabetes 
Mellitus 
56 40 9 30 4 36.4 0.609 
Hypertension 49 35 8 26.7 4 36.4 0.738 
Smoking 16 11.4 8 26.7 4 36.4 0.794 
Alcohol 22 15.7 3 10 1   9.0 0.789 
IHD 11   7.9 2   6.7 0   0 1.000 
CVA   8   5.7 3 10 0   0 0.482 
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Leukemia   0   0 0   0 0   0 1.000 
Heart Failure   3   2.1 0   0 0   0 1.000 
PVD   1   0.7 0   0 0   0 1.000 
COPD   6   4.3 2   6.7 1   9.0 0.517 
CKD   4   2.9 0   0 1   9.0 0.300 
Liver Disease   1   0.7 0   0 0   0 1.000 
Dementia   0   0 0   0 0   0 1.000 
Lymphoma   0   0 0   0 1   9.0 1.000 
 
IHD: Ischemic heart disease; CVA: Cerebrovascular Accident; PVD: Peripheral 
Vascular disease; COPD: Chronic Obstructive Pulmonary Disease; CKD: Chronic 
Kidney Disease 
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USE OF INCITING AGENTS AND HYPOKALEMIA 
 
Table 19: Univariate analysis of use of inciting agent and hypokalemia 
Agent Cases(n=181) % Control(n=20) % P 
Loop/Thiazide diuretics   16   8.8 00 00 0.377 
Steroids   15   8.3 01 05 1.000 
Inhaled Beta Agonists     7   3.9 00 00 1.000 
Amphotericin 
B/Azoles/Echinocandins 
  00   0 00 00 - 
Insulin   13   7.2 02 10 0.649 
Antibiotics(Ampicillin, 
Caebenicillin, other 
penicillin, Gentamicin) 
  13   7.2 02 10 0.649 
Cytotoxic Agents   01   6.0 00 00 1.000 
Theophylline/Aminophylline 
/Caffeine  
  09   4.9 02 10 0.300 
Hydroxycobalamine   00   0 00 00 - 
Quetiapine overdose   00   0 00 00 - 
Verapamil Overdose   00   0 00 00 - 
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USE OF INCITING AGENTS AND SEVERITY OF HYPOKALEMIA 
Table 20: Univariate analysis of use of inciting agents in the last 3 months and 
severity of hypokalemia 
Inciting 
Agent 
Mild  % Moderate  % Severe  % P 
Diuretics 12 8.6 4 13.3 0   0 0.328 
Steroids 11 7.9 2   6.7 2 18.2 0.675 
IBA   5 3.6 1   3.3 1   9.1 0.543 
Antifungals   0 0 0   0 0   0 - 
Insulin 12 8.6 1   3.3 0   0 0.671 
Antibiotics 11 7.9 2   6.7 0   0 0.919 
Cytotoxics   1 0.7 0   0 0   0 1.000 
HCB   0 0 0   0 0   0 - 
Theophylline 
group 
  6 4.3 3 10 0   0 0.322 
Quetiapine 
overdose 
  0 0 0   0 0   0 - 
Verapamil 
Overdose 
  0 0 0   0 0   0 - 
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HYPOKALEMIA AND DOSE AND ROUTE OF POTASSIUM CORRECTION 
Table 21: Dose and route of potassium correction in relation to the degree of 
hypokalemia 
Degree of 
Hypokalemia 
Route of 
Correction 
Median (IQR) 
In grams 
Standard 
deviation 
P  
Mild Total(both iv 
and oral) 
Intravenous 
Oral 
1.5 (0.0,5.6) 
 
  0.0 (0.0,3.0) 
  0.0 (0.0,0.0) 
  5.84 
 
  4.34 
  3.05 
<0.001 
 
<0.001 
  0.119 
Moderate Total(both iv 
and oral) 
Intravenous 
Oral 
  6.0 (2.9,14.9) 
 
  4.5 (1.5,10.5) 
  0.0 (0.0,0.13) 
  8.17 
 
  6.7 
  5.35 
<0.001 
 
<0.001 
  0.119 
Severe Total(both iv 
and oral) 
Intravenous 
Oral 
15.0 (3.0,29.0) 
 
  9.0 (3.0,15.0) 
  0.0 (0.0,9.0) 
18.61 
 
  8.47 
15.32 
<0.001 
 
<0.001 
  0.119 
 
iv : intravenous; IQR: inter quartile range 
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                                                              Dose ( grams) 
 
Figure 14: Total dose of potassium (both intravenous and oral) used for correction and 
their frequencies 
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Figure 15:  Intravenous dose of potassium used for correction in grams and their 
frequencies 
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Figure 16: Oral dose of potassium used for correction in grams and their frequencies 
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HYPOKALEMIA AND DURATION OF POTASSIUM CORRECTION 
Table 22: Analysis of hypokalemia and the duration of potassium correction 
Degree of 
Hypokalemia 
Median(IQR) 
In days 
Standard 
deviation 
P 
Mild 0.17 (0.0,0.5) 1.45 <0.001 
Moderate 0.50 (0.2,1.5) 1.77 <0.001 
Severe 1.17 (0.2,3.4) 4.37 <0.001 
IQR: inter quartile range 
 
                                                     Duration (days) 
Figure 17:  Duration of potassium correction and their frequencies 
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HYPOKALEMIA AND ECG CHANGES 
Table 23: ECG changes among cases and controls 
 Cases % Control % P 
Frequency 108 60 12 60 0.003 
 
 
 
 
Table 24: ECG changes among the various degrees of severity of hypokalemia 
Degree of 
hypokalemia 
Frequency % P 
Mild 82 45.3 0.923 
Moderate 18   9.9 0.923 
Severe   8   4.4 0.923 
 
 
 
83 
 
 
 
Table 25: Frequencies of the types of ECG changes occurring among cases 
Type of ECG change Frequency Percentage 
Sinus tachycardia 37 20.4 
Decreased T wave amplitude 59 32.6 
Flattening of T wave 10   5.5 
Inversion of T wave 10   5.5 
PR prolongation 03   1.7 
PR shortening 00   0 
QT prolongation 43 23.8 
U waves 02   1.1 
VPCs 05   2.8 
AF 07   3.9 
Sinus arrhythmia 05   2.8 
RBBB 02   1.1 
LBBB 02   1.1 
LVH 03   1.7 
Junctional rhythm 01   0.5 
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Table 26: Frequencies of the types of ECG changes among controls 
Type of ECG change Frequency Percentage 
Sinus tachycardia 4 20 
Decreased T wave amplitude 3 15 
Flattening of T wave 0 00 
Inversion of T wave 4 20 
PR prolongation 0 00 
PR shortening 1 05 
QT prolongation 1 05 
U waves 0 00 
VPCs 0 00 
AF 1 05 
Sinus arrhythmia 1 05 
RBBB 0 00 
LBBB 0 00 
LVH 0 00 
Junctional rhythm 0 00 
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Figure 18:  Frequencies of the types of ECG changes among cases and control groups 
in percentage 
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DISCUSSION 
 
Demographic Characteristics 
The patient population in this study had a mean age of 50 years among cases and 48 
years among control group. Most of the patients in both the groups were more than 58 
years of age (38.7% and 35 % in the cases and control groups respectively). There 
were no patients in the 38-48 years of age category among the control group. In the 
other categories of age, the percentage of patients in both the groups was similar. 
There were more males in both the groups than females which are in contrast to the 
Denmark and Glasgow studies where females were more than males. 
Representation from each medical unit in the two groups was also similar. Maximum 
number of patients in both the groups was housewives followed by manual labourers 
and farmers as well as students. There were a few people who belonged to professions 
like police, artist, army, advocate, engineer, driver, clerk, mason, lecturer, 
homeopathic doctor, mechanic, nurse and salesman. Tamil Nadu was the state which 
was maximally represented followed by Andhra Pradesh and West Bengal in both the 
groups. Minor representations from other states like Jharkhand, Orissa, Bihar, Assam 
and Tripura were also there. There were 2 patients from other countries like Nepal and 
Bangladesh.  
Proportion of patients with hypokalemia 
The total admissions in the medical wards during the time period when this study was 
done was 377 out of which patients with hypokalemia on day 1 of hospital admission 
were 181. Therefore, the proportion of hypokalemics was 48% ( CI 0.42-0.53) of the 
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total admissions in the general medical wards. This is higher than what has been 
described in earlier studies with the study in Glasgow showing the proportion as 21% , 
one done in Jakarta showing 23% and the Denmark study 16.8%.  
 Amongst the hypokalemics, the proportion of patients with mild, moderate and severe 
hypokalemia were 37% (CI 0.32-0.42), 8% (CI 0.05-0.11) and 3% (0.01-0.05) 
respectively. The proportion of patients in the severe category was similar to the 
Denmark study, which is definitely lower than the ones reported in earlier studies- 
24.9% and 9.4% 
The underlying causes of hypokalemia (based on treating physician’s assessment) 
The most common likely underlying cause for hypokalemia was undetermined 
comprising 80. 7% (possibilities were sweating and starvation). Amongst the named 
causes were gastrointestinal losses in the form of vomiting (33.7%) and loose stools 
(15.5%). Next to these was cerebrovascular accident (14.4%). Renal losses as the 
underlying cause were lesser in number, salt wasting nephropathy (11.6), osmotic 
diuresis(7.2%),proximal RTA (1.1%), distal RTA(0.6%). Among the drug related 
causes, diuretics were maximum (7.7%) followed by usage of insulin (6.1%) and 
steroids (5.5%) 
Our study showed contrasting results compared to the Glasgow study where the most 
common likely underlying cause was found to be drugs (38%) with diuretics 
accounting for 62% cases, steroids 9 %, insulin 7% and hydroxycobalamine 7%.  
Gastrointestinal losses occurred only in 16.8% of cases. Renal losses accounted for 
2.3% of cases.  
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Hypokalemia and Mortality 
In this study, the mortality rate among cases was 4.4% and that among control was 
0.4%. The difference in the mortality rates in between the two groups was not 
statistically significant. This could possibly be due to the fact that the control group 
had lesser number of patients compared to the cases group.  
 Among the various severity grades of hypokalemia, the mortality rate in the mild, 
moderate and severe hypokalemia groups were 3.9%, 0%, and 0.04% respectively. 
These differences were not statistically significant. This is in contrast to the results 
obtained from the Glasgow study which showed a statistically significant increased 
mortality among patients who had severe hypokalemia. The Denmark study too 
showed similar results but was not shown to be statistically significant. This was 
probably due to the number of fatal events being too less.  
Mean survival time in the cases group was 47.65 days (CI 34.5-60.7) and in the 
control group was 56.84 days (49.0-64.8). The same was 44.5 (CI 29.5-59.5) and 24.0 
(CI 24.0-24.0) in the mild and severe hypokalemia groups respectively. The moderate 
hypokalemia group did not have any deaths and hence, the mean survival time for this 
group was not calculated. 
Hypokalemia and Co-morbidities 
The distribution of co-morbidities among cases and control groups were mostly 
similar except cerebrovascular accident and heart failure which were more in the cases 
group. A univariate analysis of these co-morbidities did not show any statistically 
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significant difference between hypokalemics and non-hypokalemics as well as the 
various degrees of severity of hypokalemia.  
Use of Inciting agents and hypokalemia 
The most common inciting agent used within the last 3 months prior to hospital 
admission among hypokalemics was diuretics followed by steroids. The control group 
had more usage of insulin, antibiotics (penicillin derivatives) and theophylline group 
of drugs. A univariate analysis between the two groups did not show any statistically 
significant difference. 
Among the various degrees of severity of hypokalemia,  mild and moderate 
hypokalemics had more usage of diuretics whereas the severe hypokalemia group had 
more usage of steroids and no diuretics at all. A univariate analysis failed to reveal 
any statistically significant difference between the three groups. 
Hypokalemia and dose, route of potassium correction 
MILD HYPOKALEMIA 
Among patients with mild hypokalemia, the total dose of potassium (intravenous plus 
oral) required for normalising serum potassium in 75% of patients was 5.6 grams. 
Through the intravenous route, 75% of patients required a dose of 3.0 grams. 
Through the oral route, 75% of patients did not require any oral correction at all. 
The results were statistically significant for total and intravenous doses but not for the 
oral dose. 
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MODERATE HYPOKALEMIA 
Among patients with moderate hypokalemia, 75% of patients required a total 
(intravenous plus oral) dose of 14.9 grams of potassium for normalising serum 
potassium.  
For the intravenous route, 75% of patients needed 10.5 grams of potassium correction 
For oral route, 75% of patients required 0.13 grams of potassium correction. 
These results were again statistically significant for the total and intravenous doses but 
not for the oral dose. 
SEVERE HYPOKALEMIA 
In the severe hypokalemia group, 75 % of patients needed a total (intravenous plus 
oral) of 29.0 grams of potassium correction. 
For intravenous route, 75% of patients required 15.0 grams of potassium, and for oral 
route, 75% of patients needed 9 grams of potassium for achieving eukalemia. 
In this group too, the results were statistically significant in the total and intravenous 
doses but not for oral doses. 
The amount of potassium required for correcting severe hypokalemia was about 7 
times that required for correcting mild hypokalemia and 2.5 times that need for 
correcting moderate hypokalemia. 
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Intravenous dose needed to correct severe hypokalemia was about 2 times more than 
the moderate ones. Intravenous correction was hardly required in the mild 
hypokalemics. 
Oral correction was not need in the mild hypokalemics, very minimally required in the 
moderate ones. For severe hypokalemics, oral doses were also required for correction 
along with intravenous doses. 
Hypokalemia and duration of potassium correction 
MILD HYPOKALEMIA 
75% of patients required potassium correction for 0.5 days to achieve eukalemia. 
MODERATE HYPOKALEMIA 
75% of patients required potassium correction for 1.5 days to achieve eukalemia. 
SEVERE HYPOKALEMIA 
75% of patients required potassium correction for 3.4 days to achieve eukalemia. 
All the above results were statistically significant 
Hypokalemia and ECG changes 
The ECG changes occurred in 60% of cases and 60% of control population. This 
result was statistically significant. The same occurring in the mild, moderate and 
severe hypokalemia groups were 45.3%, 9.9%, and 4.4% respectively stating that the 
same occurred more in the mild hypokalemia group. However, this finding was not 
statistically significant. 
92 
 
The most common ECG abnormality among patients with hypokalemia was decreased 
T wave amplitude followed by QT prolongation. Among the control group the most 
common ECG abnormality was sinus tachycardia followed by inversion of T wave. In 
literature, the earliest change that has been described to occur in hypokalemia is a 
decrease in the amplitude of T wave. Prolongation of QU interval has also been 
described (pseudo QT prolongation).  
In this study, there did not seem to be difference in the number of ECG changes 
occurring among cases and control groups and though there were an increased number 
of ECG changes occurring among patients with mild hypokalemia than other degrees 
of severity of the same, this finding was not found to be statistically significant.   
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LIMITATIONS 
 
This study had the following limitations: 
1) Since this is an observational study, the findings of the same may have a 
likelihood of being biased. Therefore, further stronger studies need to be done 
to confirm the same. 
2) The underlying cause was determined on a subjective assessment of the 
physician managing the patient in the medical wards. A more objective method 
like the measurement of trans tubular potassium gradient (ttkg) may need to be 
done in future studies to determine the same in individual patients. 
3) The assessment of the ECG findings was done by the physicians in charge of 
the patient in the ward and there was no confirmation by an electro 
physiologist. Future studies may need confirmation of the same by such 
professional to eliminate any errors as well as bias. 
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CONCLUSIONS 
The following conclusions are drawn from this study: 
1) The proportion of patients with hypokalemia on day 1 of hospital admission 
was higher than previous studies. However, the proportion of severe 
hypoklaemics  was similar to the Denmark study and lesser than earlier studies. 
The reason for this possibly could be that the previous studies community and 
hospital acquired hypokalemias together in their study. This differentiation was 
done  in the Denmark study 
2) The most common underlying cause of hypokalemia was undetermined causes 
seconded by gastrointestinal losses in the form of vomiting and loose stools. 
The use of objective methods like the determination of the transtubular 
potassium gradient (ttkg) in future studies may help to invade the territory of 
the undetermined causes as well as confirm the remaining causes which were 
subjectively assessed by the treating physician. 
3) In this study, the mortality rate among hypokalemics was more than the non 
hypokalemics. However, this difference was not statistically significant. The 
mortality rate was, in contrast, more in the mild hypokalemics that the  patients 
with severe hypokalemia. This difference too was not found to be statistically 
significant. These results obtained are in contrast to what was seen in the 
previous studies. 
4) There was no statistically significant association established in between co-
morbidities and hypokalemia. 
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5) Mild hypokalemics may not need any potassium correction or if at all they 
need, may need a very minimal dose of about 1.5 grams. Moderate 
hypokalemics may need minimal intravenous plus oral correction (about 4 
times more than that needed for mild hypokalemia and 2.5 times less than that 
needed for severe hypokalemics) for normalising serum potassium with 
intravenous route as the main route of administration. Severe hypokalemics 
may need both intravenous and oral forms of potassium at higher doses for 
achieving eukalemia(10 times that needed for mild hypokalemia and 2.5 times 
that needed for moderate hypokalemia) with intravenous route as the main 
route of administration. 
6)  At an average mild hypokalemics become eukalemic within 4 hours, moderate 
hypokalemics within 12 hours and severe hypokalemics within 28 hours 
following potassium correction. 
7) There was no difference in the number of patients showing ECG changes 
between hypokalemics and non hypokalemics but decreased T wave amplitude 
and QT prolongation was more common in hypokalemics. Occurance of u 
wave was seen only in hypokalemics 
8) There was no significant association between use of inciting agents and 
hypokalemia as well as its severity. 
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ANNEXURES 
CLINICAL RESEARCH FORM 
Annexure 1 
Data Abstraction sheet. 
Name:                                                 Age:           Sex: M / F     DOA/1st visit: …. /… /2015 
 
Hosp No:                                   Occupation: HW/Man labour/Student/Business/Farmer/…... 
State: TN/AP/WB/…………….                 Unit: Med 1 / Med 2 /Med 3/ Med 4/ Med 5 
Contact Number:                                        Address: 
                                                                     Village/ town:     
Comorbidity  Number of years Comorbidity  Number of 
years 
Diabetes mellitus Yes/ No  Heart Failure Yes/ No  
Hypertension Yes/ No  Peripheral 
Vascular 
Disease 
Yes/ No  
Smoking Yes/ No  Chronic 
Obstructive 
Pulmonary 
Disease 
Yes/ No  
Alcohol Yes/ No  Chronic 
Kidney 
Disease 
Yes/ No  
Ischaemic  
Heart 
Disease 
 
Yes/ No 
 Liver Disease, 
Non alcohol 
related 
Yes/No  
Cerebrovascular 
Accident 
 
Yes/ No 
 Dementia Yes/ No  
Leukemia Yes/ No  Lymphoma Yes/ No  
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Use of inciting drugs in the past 3 months: 
 
 
Loop diuretics / Thiazides         Yes / No 
Steroids         Yes / No 
Inhaled Beta 2 agonists         Yes / No 
Amphotericin B/Azoles/Echinocandins( 
specify) 
        Yes / No 
Insulin         Yes / No 
Antibiotics (Ampicillin, Carbenicillin, other 
penicillin, gentamicin- specify name) 
        Yes / No 
Cytotoxic agents (Cisplatin)         Yes / No 
Hydroxycobalamine         Yes / No 
Theophylline/aminophylline/ caffeine( 
specify) 
        Yes/ No 
Quetiapine overdose         Yes/ No 
Verapamil overdose         Yes/ No 
 
Symptoms (duration)  Cardiovascular 
system 
S1/S2/S3/S4 
Murmurs 
Arrhythmias 
Pulse rate 
(beats/minute) 
 
rhythm  
 
 
 
 
 
Regular/ irregular 
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Respiratory rate  
(breaths/ minute) 
 Per abdomen 
Bowel sounds 
 
Present/ Absent 
Blood Pressure 
( mm Hg) 
 CNS(if abnormal 
specify) 
 
Sensorium(GCS) 
 
Motor 
 
Sensory 
 
Bladder 
 
Cerebellar 
 
Extra pyramidal 
 
Abnormal movents 
 
 
 
 
                                          
Normal/ Abnormal 
 
Normal/ Abnormal 
 
Normal/ Abnormal 
 
Normal/ Abnormal 
 
Normal/ Abnormal 
 
Present( specify)/ 
Absent 
Temperature  
( degree Fahrenheit) 
 ECG( if abnormal 
specify) 
 rate 
 
rhythm 
 
Intervals(PR,QT) 
 
 segments(QRS, ST) 
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Waves( P,T,U) 
General examination 
 
Pallor 
 
skin turgor 
 
 
 
Yes/ No 
 
Normal/Abnormal 
Any other atypical 
finding 
 
 
 
 
HB/TC/DC/Patelets  Urine Ca/Urine Cl/ K+  
LFT  Urine osmolality/ 
serum osmolality 
 
Urea/Creatinine  Trans tubular 
potassium gradient 
 
 
ABG  TSH/A1c/Cortisol 
 
 
Na/K/Bicarbonate  Ultrasound abdomen 
 
 
 
Mg/Ca/PO4  Any other relevant 
test 
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Urine K/ creatinine; 
Ratio 
   
 
 
Dose of Potassium Required  Duration   Route 
 
 
 
 
  
 
 
 
 
FINAL DIAGNOSIS  
FINAL OUTCOME       Death/ Discharged 
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CONSENT FORM 
Annexure 2 
 
Informed Consent form to participate in a research study  
 
Study Title: “Prospective Observational study to determine the causes of hypokalemia in 
medical wards and its association with other comorbidities and death” 
 
 
Study Number: ____________ 
 
Subject’s Initials: __________________ Subject’s Name: _________________________________________ 
 
Date of Birth / Age: ___________________________ 
 
(Subject) 
 
(i)  I confirm that I have read and understood the information sheet dated ____________ 
for the above study and have had the opportunity to ask questions. [  ] 
 
(ii)  I understand that my participation in the study is voluntary and that I am free to 
withdraw at any time, without giving any reason, without my medical care or 
legal rights being affected. [  ] 
 
(iii)  I understand that the Sponsor of the clinical trial, others working on the 
Sponsor’s behalf, the Ethics Committee and the regulatory authorities will not 
need my permission to look at my health records both in respect of the current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the trial. I agree to this access. However, I understand that my 
identity will not be revealed in any information released to third parties or 
published. [  ] 
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(iv)  I agree not to restrict the use of any data or results that arise from this study 
provided such a use is only for scientific purpose(s). [  ] 
 
(v)  I agree to take part in the above study. [  ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable  
 
Date: _____/_____/______ 
 
 
 
 
 
Signatory’s Name: _________________________________         Signature:  
 
Or 
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Representative: _________________ 
 
Date: _____/_____/______ 
 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
 
Date: _____/_____/______ 
 
Study Investigator’s Name: _________________________ 
 
 
Signature or thumb impression of the Witness: ___________________________ 
 
Date: _____/_____/_______ 
 
Name & Address of the Witness: ______________________________ 
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PATIENT INFORMATION SHEET 
Annexure 3 
 
 CHRISTIAN MEDICAL COLLEGE, VELLORE  
Department of General Medicine 
 TITLE: Prospective Observational study to determine the causes of hypokalemia in 
medical wards and its association with other comorbidities and death 
 
INFORMATION SHEET  
You are being requested to participate in a study to see the different causes of decreased 
potassium in the body. In this study, we will be seeing the factors that may affect this salt in 
our body which will include your age, gender and the place that you come from along with 
the various diseases that you already have in your body like high blood pressure or high 
blood sugars. Some other information like the medications you have been taking, any 
addicitions that you have and the reason as to what problem in your body brought you to 
the hospital will be asked. You will be examined physically for checking for the defect in any 
system in your body. We hope to include about 200 people from this hospital in this study.  
 
Will there be any additional tests done in this study? We will not be conducting any 
additional tests in this study. All tests that are necessary to be done will be done by the 
concerned unit that you are admitted under.  
 
Are there any side effects? Since we will only be observing the disease process in your 
body and we will not be giving you any additional medication, as a part of the study, there 
are no side effects. 
 
If you take part what will you have to do? If you agree to participate in this study, you 
will be asked the details about the disease in your body and you will be examined physically 
for checking for the presence of any problem in your body. This information along with 
your test findings will be asked till the time that you are admitted in the hospital.  
 
Can you withdraw from this study after it starts? Your participation in this study is 
entirely voluntary and you are also free to decide to withdraw permission to participate in 
this study. If you do so, this will not affect your usual treatment at this hospital in any way.  
 
What will happen if you develop any study related injury? We do not expect any injury 
to happen to you  because of the study as we are only observing the disease that has 
afftected you and we will not be asking you to take any new medications apart from the 
ones prescribed by thr unit under whom you are admitted. 
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Will you have to pay any amount for the study? For being in the study, you do not have 
to pay any amount. You will have to pay only what your concerned unit under whom you 
have been admitted charges for your hospital stay and treatment and nothing extra to that 
amount. 
 
What happens after the study is over? Once the study is over, we will look through the 
data that has been obtained to see how this salt( potassium) is affected in our body. With 
the information obtained we may be able to find new causes as well as develop newer tools 
for management of the condition. 
 
Will your personal details be kept confidential? The results of this study will be 
published in a medical journal but you will not be identified by name in any publication or 
presentation of results. However, your medical notes may be reviewed by people associated 
with the study, without your additional permission, should you decide to participate in this 
study.  
 
 
If you have any further questions, please ask Dr.Roshni  (telephone/mobile no.: 0416 
2282039/ 9566571708), email: med3@cmcvellore.ac.in 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
